Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 741

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 741
---
 21.9 | % |     |      64.5 | % |     |     95.6 | % |
| Psychiatry        |     |      |     |     52.7 | % |     |      26.8 | % |     |      56.3 | % |     |     91.2 | % |
| Endocrine         |     |      |     |     43.3 | % |     |      26.6 | % |     |      66.2 | % |     |     86.3 | % |
| Neurology         |     |      |     |     47.7 | % |     |      26.8 | % |     |      53.1 | % |     |     86.7 | % |
| Oncology          |     |      |     |     48.8 | % |     |      24.6 | % |     |      47.7 | % |     |     92.0 | % |
| Cardiovascular    |     |      |     |     50.0 | % |     |      21.0 | % |     |      55.2 | % |     |     82.5 | % |
| Urology           |     |      |     |     40.9 | % |     |      15.0 | % |     |      69.2 | % |     |     84.6 | % |

As can be seen, the success rates of clinical trials differ according to the disease area and according to the phase. The average success rates are represented by “All Indication” in which the probability of success of Phase I is 52% and those of Phase II and Phase III are 28.9% and 57.8% respectively. For the IsletRx (diabetes) development we used the Endocrine success rates from the above table.

| Moore Financial Consulting |

____________ 5Clinical Development Success rates and Contributing factors 2011–2020/BIO, February 2021 Annex E-25

Another one of the BIO research results is the rates of success of clinical trials for rare diseases. In this context the BIO research reads “ …rare diseases can be identified based on meeting either or both of the following standard criteria: affecting fewer than 200,000 people in the US, or prevalence of 1 in